To reduce the use of Chemotherapy in elderly patients with ER-positive and HER2-positive breast cancer

IBCSG 55-17 TOUCH

Coordinating investigator

Dr. med.
Patrik
Weder
Kantonsspital St. Gallen
+41 71 494 18 80

Phase II open-label, multicenter, randomized trial of neoadjuvant palbociclib in combination with hormonal therapy and HER2 blockade versus paclitaxel in combination with HER2 blockade for elderly patients with hormone receptor positive/HER2 positive early breast cancer

For further information on the IBCSG 55-17 TOUCH trial, please consult the IBCSG website.

Clinics

All trials

More trials: Breast cancer

Pregnancy outcomes and safety of interrupting endocrine therapy for women with who desire pregnancy
IBCSG 48-14 POSITIVE - BIG 8-13
Treatment of patients with bone metastases using Xgeva®
SAKK 96/12
A phase I trial with TLD-1, a novel liposomal doxorubicin, in patients with advanced solid tumors
SAKK 65/16
Surgical lymph node removal with the option of “extensive operation” or “radiotherapy” in breast cancer patients with existing axillary lymph node involvement
SAKK 23/16 TAXIS
Exercise regimen for the reduction of the side effects of aromatase inhibitor treatment in patients with early breast cancer
SAKK 95/17
Metastatic breast cancer: chemotherapy or anti-hormonal treatment in combination with ribociclib
SAKK 21/18
A phase III trial, which tests the safety and efficacy of an investigational combination of drugs for a specific form of breast cancer
IBCSG 59-19 POLAR